Literature DB >> 22152297

Species differences in the effects of bezafibrate as a potential treatment of mitochondrial disorders.

Fatima Djouadi, Jean Bastin.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 22152297     DOI： 10.1016/j.cmet.2011.11.003

Source DB:  PubMed          Journal:  Cell Metab        ISSN： 1550-4131            Impact factor:   27.287


× No keyword cloud information.
  12 in total

Review 1.  The Role of Oxidative Stress and Bioenergetic Dysfunction in Sulfite Oxidase Deficiency: Insights from Animal Models.

Authors:  Angela T S Wyse; Mateus Grings; Moacir Wajner; Guilhian Leipnitz
Journal:  Neurotox Res       Date:  2018-12-05       Impact factor: 3.911

Review 2.  Mitochondrial Genetic Disorders: Cell Signaling and Pharmacological Therapies.

Authors:  Fatima Djouadi; Jean Bastin
Journal:  Cells       Date:  2019-03-28       Impact factor: 6.600

Review 3.  Mitochondrial Diseases Part III: Therapeutic interventions in mouse models of OXPHOS deficiencies.

Authors:  Susana Peralta; Alessandra Torraco; Luisa Iommarini; Francisca Diaz
Journal:  Mitochondrion       Date:  2015-01-29       Impact factor: 4.160

Review 4.  The spectrum of pyruvate oxidation defects in the diagnosis of mitochondrial disorders.

Authors:  Wolfgang Sperl; Leanne Fleuren; Peter Freisinger; Tobias B Haack; Antonia Ribes; René G Feichtinger; Richard J Rodenburg; Franz A Zimmermann; Johannes Koch; Isabel Rivera; Holger Prokisch; Jan A Smeitink; Johannes A Mayr
Journal:  J Inherit Metab Dis       Date:  2014-12-20       Impact factor: 4.982

Review 5.  Therapies in inborn errors of oxidative metabolism.

Authors:  Manuel Schiff; Paule Bénit; Howard T Jacobs; Jerry Vockley; Pierre Rustin
Journal:  Trends Endocrinol Metab       Date:  2012-05-25       Impact factor: 12.015

Review 6.  Turn up the power - pharmacological activation of mitochondrial biogenesis in mouse models.

Authors:  J C Komen; D R Thorburn
Journal:  Br J Pharmacol       Date:  2014-04       Impact factor: 8.739

7.  RETRACTED: Bezafibrate improves mitochondrial function in the CNS of a mouse model of mitochondrial encephalopathy.

Authors:  Natalie Noe; Lloye Dillon; Veronika Lellek; Francisca Diaz; Aline Hida; Carlos T Moraes; Tina Wenz
Journal:  Mitochondrion       Date:  2012-12-20       Impact factor: 4.160

8.  Copper and bezafibrate cooperate to rescue cytochrome c oxidase deficiency in cells of patients with SCO2 mutations.

Authors:  Alberto Casarin; Gianpietro Giorgi; Vanessa Pertegato; Roberta Siviero; Cristina Cerqua; Mara Doimo; Giuseppe Basso; Sabrina Sacconi; Matteo Cassina; Rosario Rizzuto; Sonja Brosel; Mercy M Davidson; Salvatore Dimauro; Eric A Schon; Maurizio Clementi; Eva Trevisson; Leonardo Salviati
Journal:  Orphanet J Rare Dis       Date:  2012-04-19       Impact factor: 4.123

9.  Long-term bezafibrate treatment improves skin and spleen phenotypes of the mtDNA mutator mouse.

Authors:  Lloye M Dillon; Aline Hida; Sofia Garcia; Tomas A Prolla; Carlos T Moraes
Journal:  PLoS One       Date:  2012-09-04       Impact factor: 3.240

Review 10.  Resveratrol and Myopathy.

Authors:  Jean Bastin; Fatima Djouadi
Journal:  Nutrients       Date:  2016-04-28       Impact factor: 5.717
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.